Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 54Terminated 15Active not recruiting 4Withdrawn 3Recruiting 2Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid 1Hematologic Neoplasms 1

Interventions

Dexamethasone 16daratumumab 14Bortezomib 11Lenalidomide 9pomalidomide 7Calcium Dobesilate 6isatuximab 4belantamab mafodotin 4Cyclophosphamide 4carfilzomib 3Melphalan 3tocilizumab 2iberdomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2Biopsy 2zanubrutinib 1trametinib 1talquetamab 1selinexor 1pembrolizumab 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Multiple Myeloma × Whole-Body Irradiation × Clear all
NCT04579523 2026-06-04

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡